Organization

DEUTSCHES RHEUMA FORSCHUNGSZENTRUMBERLIN

Berlin-based research institute specializing in rheumatic and autoimmune diseases, combining immunology expertise with computational approaches to predict treatment outcomes.

Research institutehealthDE

H2020 projects

As coordinator

Total EC funding

€763K

Unique partners

What they do

Their core work

The German Rheumatism Research Centre Berlin (DRFZ) is a specialized biomedical research institute focused on understanding autoimmune and inflammatory diseases, particularly rheumatoid arthritis. They investigate immune tolerance mechanisms, disease trajectories, and treatment response patterns using advanced computational and genomic approaches. Their work spans from fundamental immunology — such as characterizing regulatory plasma cells — to applied predictive modeling that aims to explain why some patients don't respond to treatments or experience relapses.

Core expertise

What they specialise in

Rheumatoid arthritis and autoimmune disease researchprimary

2 projects

RTCure focused specifically on rheumatoid arthritis tolerance mechanisms, and 3TR addresses autoimmunity, inflammation, and treatment non-response across autoimmune conditions.

Immune tolerance and B cell biologyprimary

2 projects

PREG-LAB studied regulatory plasma cells and pro-inflammatory B cells in immunity, while RTCure explored tolerance mechanisms as a path toward rheumatoid arthritis cure.

Disease stratification and predictive modelingemerging

1 project

3TR project involves disease trajectory analysis, stratification, and predictive modeling to identify molecular mechanisms behind treatment non-response and relapses.

Single-cell and integrative genomicsemerging

1 project

3TR project keywords include single-cell data and integrative genomics, indicating adoption of high-resolution molecular profiling techniques.

Allergy and inflammation biologysecondary

1 project

3TR project scope extends to allergy alongside autoimmunity and inflammation, broadening DRFZ's disease coverage beyond rheumatic conditions.

Evolution & trajectory

How they've shifted over time

Early focus

B cell immunology and tolerance

Recent focus

Precision medicine and disease modeling

DRFZ's early H2020 work (2016–2017) centered on fundamental immunology — characterizing specific immune cell populations (regulatory plasma cells, B cells) and exploring tolerance as a therapeutic concept for rheumatoid arthritis. By their most recent project (3TR, started 2019), the focus shifted decisively toward data-intensive, systems-level approaches: single-cell genomics, integrative multi-omics, predictive modeling, and patient stratification. This trajectory reflects a broader move from "understanding immune mechanisms" to "predicting and personalizing treatment outcomes."

DRFZ is moving from classical immunology toward computational and multi-omics approaches for predicting treatment response in autoimmune diseases — positioning them at the intersection of rheumatology and precision medicine.

Collaboration profile

How they like to work

Role: specialist_contributorReach: European19 countries collaborated

DRFZ participates exclusively as a consortium partner, contributing specialized rheumatology and immunology expertise rather than leading projects. With 98 unique partners across 19 countries from just 3 projects, they operate in large-scale European research consortia — their average consortium size is substantial. This pattern suggests they are a trusted specialist that major consortia seek out for deep domain knowledge in autoimmune disease biology.

Despite only 3 projects, DRFZ has built a remarkably broad network of 98 unique partners across 19 countries, reflecting their participation in large pan-European health consortia. Their collaborative reach spans most of the EU, with no apparent geographic restriction.

Why partner with them

What sets them apart

DRFZ is one of very few research centres in Europe dedicated entirely to rheumatic and musculoskeletal diseases, giving them unmatched depth in autoimmune disease biology. Their combination of classical immunology expertise (B cell biology, tolerance mechanisms) with emerging computational capabilities (single-cell genomics, agent-based modeling) makes them a rare bridge between wet-lab rheumatology and data-driven precision medicine. For any consortium needing deep autoimmune disease expertise grounded in decades of focused research, DRFZ is a natural first choice in Germany.

Notable projects

Highlights from their portfolio

3TR
Large-scale project (2019–2026) tackling treatment non-response across autoimmune diseases with advanced multi-omics and predictive modeling — represents DRFZ's strategic shift toward precision medicine.
RTCure
Largest single EC contribution to DRFZ (EUR 453,450), directly targeting a cure for rheumatoid arthritis through immune tolerance — their core mission.
PREG-LAB
ERC Consolidator Grant-linked project studying regulatory plasma cells, reflecting fundamental research excellence in B cell immunology.

Cross-sector capabilities

Digital health and AI-driven patient stratificationBioinformatics and single-cell data analysisComputational modeling of biological systemsAllergy diagnostics and immunotherapy

Analysis note: Profile based on only 3 H2020 projects, all as participant. DRFZ is a well-known institute with extensive research output beyond H2020, so this profile likely underrepresents their full capabilities. The early/recent keyword split is limited because all keyword data falls into the recent period. Confidence would increase substantially with access to their full publication record or national funding portfolio.